International Journal of Advanced Research in Engineering Technology & Science

ISSN: 2349-2819

Email: editor@ijarets.org Volume-11, Issue-2 February – 2024 www.ijarets.org

EXPERIMENTAL INVESTIGATION ON FORMULATION, OPTIMIZATION AND CHARACTERIZATION OF CHOLECALCIFEROL TRANSDERMAL PATCHES

Saurabh Soni

Research Scholar

School of Pharmacy, Glocal University Mirzapur Pole, Saharanpur (U.P)

Prof. (Dr.) Jitendra K. Malik

Research Supervisor

School of Pharmacy, Glocal University Mirzapur Pole, Saharanpur (U.P)

ABSTRACT:

The proposed work was aimed to optimization formulation and characterization of transdermal patches of cholecalciferol for efficient transdermal delivery of drug. Solubility suggested that cholecalciferol uninhibitedly dissolvable in organic solvents, dissolvable in phosphate support pH 6.8 and for all intents and purposes insoluble in distilled water. The log p estimation of cholecalciferol 3.7, it was closer to standard worth. Log P value in a range of 1 to 4 indicates higher permeation through the skin. A regression coefficient (R^2) at 280 nm was found to be 0.993. The Correlation Coefficient (R2) = 0.993 and Y = 0.022x + 0.056 Regression co-efficient (R2) for the medication in phosphate support 6.8 was seen as close to one and in the linearity extend, which show direct connection absorbance and concentration. In this current exploration work specific DMSO and DMF was select. This was obvious from the aftereffects of cholecalciferol pemeation at 16 hrs from PEC2 to PEC7 with DMSO thus at various groupings of 10 % w/w and 20 % w/w of all out weight of polymer dry weight. It likewise that DMF as was not adequate to accomplish want permeation flux for controlled delivery up to 16 hrs. If there should be an occurrence of weight variety, study drug loaded patche (4 cm^2) were gauging utilizing electronic balance. The weight of all groups discovered uniform in a range of 321 mg to 363 mg. drug content outcomes additionally discovered uniform in all clusters in a range of 97 % to 98 %, it proposed that the medication and polymers consistently distributed in dispersion. Generally speaking, the aftereffects of starter preliminary result proposed that batches arranged with ERL 100 shows great mechanical properties contrast with different polymers however helpless glue properties.

Keywords: TDDS, cholecalciferol , ERL100, Iron Based Cholecalciferol

INTRODUCTION:

The Skin is one of the most extensive organs of the human body. This multilayered organ receives approximately one-third of all blood circulating through body. With a thickness of about a millimeter, the skin separates the underlying blood circulation network from the outside environment. Transdermal delivery of drugs through the skin to the systemic circulation provides a convenient route of administration for a variety of clinical indications. Transdermal delivery systems are currently available containing scopolamine (hyoscine) for motion sickness, clonidine and nitroglycerin for cardiovascular

disease, fentanyl for chronic pain, nicotine to aid smoking cessation.
Design of Transdermal Drug Delivery System: [1, 2, 8] All
transdermal drug delivery systems consist mainly of -
Polymer matrix
Drug
Enhancers and other excipients
Other excipient

Polymer matrix:-

Polymer is an integral and foremost important component of transdermal drug delivery systems. Different classes of polymeric materials have been used to achieve rate controlled drug delivery. The mechanism of drug release depends upon the physicochemical properties of the drug and polymer used in the manufacture of the device. The following criteria should be satisfied for a polymer to be used in a transdermal system [3].

Molecular weight, glass transition temperature, chemical functionality or polymer must allow diffusion and release of the specific drug.

The polymer should permit the incorporation of a large amount of drug.The
polymer should not react, physically or chemically with the drug

The polymer should be easily manufactured and fabricated into the desired product and in expensive. The polymer must be stable and must not decompose in the presence of drug and other excipientsused in the formulation.

Polymers and its degradation products must be non-toxic.

Natural polymers:-

Cellulose derivates, Zein, Gelatin, Shellac, Proteins, Gums and their derivates, natural rubber and starch etc. Recently some natural polymer latex like jackfruit latex, plum latex and other semisynthetic polymers have undertaken for research to be utilized in TDDS.

Synthetic elastomers:-

Polybutadiene, Hydrin rubber, Polysiloxane, Silicone rubber, Nitrile, Acrylonitrile, Buty rubber, Styrenebutadiene rubber, Neoprene etc.

Synthetic polymers:-

Polyvinyl alcohol, Polyvinyl chloride, Polyethylene, Polyacrylate, Polyamide, Polyurea, Polyvinylpyrrolidone, Polymssethacrylate, Epoxy etc Polyvinyl alcohol, polyvinyl chloride, polyethylene, polyvinylpyrrolidone [5].

The Drug:-

For successfully developing a transdermal drug delivery system, the drug should be chosen with greatcare. The following are some of the desirable properties of a drug for transdermal delivery.

Physicochemical properties:-

The drug should have some degree of solubility in both oil and water (ideally greater than 1 mg/ml).

Substances having a molecular weight of less than 1000 units are suitable.

The substance should have melting point less than 200 °F. Concentration gradient across themembrane is directly proportional to the log solubility of drug in the lipid phase of membrane.

A saturated aqueous solution of the drug should have a pH value between 5 and 9. Drugs highly acidicor alkaline in solution are not suitable for TDD; because they get ionized rapidly at physiological pH and ionized materials generally penetrate the skin poorly[6].

Hydrogen bonding groups should be less than 2.

Biological properties:-

Drug should be very potent, i.e., it should be effective in few mgs per day (ideally less than 25

mg/day)
The drug should have short biological half-life.
The drug should be non-irritant and non-allergic to human skin.The
drug should be stable when in contact with the skin.
The drug should not stimulate an immune reaction to the skin.
Tolerance to drug must not develop under near zero order release profile.
The drug should not get irreversibly bound in the subcutaneous tissue [7].
The drug should not get extensively metabolized in the skin [2,8].

MATERIALS AND METHODS:

Table 1: List of Materials Used in Study of Transdermal Patch of Cholecalciferol

S. No.	Materials	Manufacturer
1	Cholecalciferol	Chemo Pvt Ltd, Mumbai
2	Eudragit RL 100	Chemdyes corporation, Rajkot, India
3	HPMC K15M	LOBA Chemie Pvt. Ltd.,Mumbai,India
4	Propylene glycol	Chemdyes corporation, Rajkot, India
5	PEG 400	Chemdyes corporation, Rajkot, India
6	Ethanol	Chemo Pvt Ltd, Mumbai
7	$FeCl_3.6H_2O$ and $FeCl_2.4H_2O$	Merck, Germany
8	MTT	ChemdyesPvt LTD. Rajkot
9	1-ethyl-3-[3-(dimethylamino) propyl] carbodiimide (EDC)	ChemdyesPvt LTD. Rajkot
10	N-hydroxysuccinimide (NHS)	ChemdyesPvt LTD. Rajkot
11	Acetone	ChemdyesPvt LTD. Rajkot
12	Ammonium hydroxide	ChemdyesPvt LTD. Rajkot
13	Iso propyl alcohol	Ranchem , New Delhi
14	Hydrochloric acid	National Organic Chemicales,Taiwan

FORMULATION OF NANO-PARTICLES OF IRON BASED CHOLECALCIFEROL:

Synthesis of bare Fe_3O_4:

Bare Fe_3O_4 by utilizing controlled co-precipitation technique was readied. $FeCl_2.4H_2O$ (0.4 g) and $FeCl_3.6H_2O$ (1.1 g) with molar proportion 2Fe (III):1Fe (II) in 150 mL deionized water were blended as a watery arrangement. This arrangement was kept up at 60°C (a steady temperature) for 15 min under lively blending. At that point, an answer of ammonium hydroxide (20 mL NH_4OH [25%]) was added under fiery blending and N_2 gas until the pH came to 11[9]. Subsequent to shaping dark suspension blended for 2 hr at 60°C, under past conditions. Fe_3O_4 nanoparticles were isolated from the fluid arrangement by an outside magnet. After that washed with deionized water a few times and dried in a vacuum stove short-term.

Synthesis of cholecalciferol -coated Fe_3O_4 Nanoparticles:

Cholecalciferol-covered NPs were incorporated by utilizing an in situ, one-pot with controlled co-precipitation blend strategy. From the outset, $FeCl_2.4H_2O$ (0.4 g) and $FeCl_3.6H_2O$ (1.1 g) with molar proportion 2Fe (III):1Fe (II) in 150 mL deionized water were disintegrated and this arrangement was mixed energetically for 15 min under N2 air at 60°C. From that point forward, 1.4 g of arginine was immediately added to the blend and the response was mixed for another 20 min. At that point, an answer of 20 mL of ammonium hydroxide (NH_4OH, 25%) was added drop-wise under fiery mixing and nitrogen gas, until the pH came to ~11. In the wake of framing dark suspension was warmed for 6hr at 60°C while mixing [10]. At last, cholecalciferol-covered NPs were secluded by setting a magnet. At that point, these

nanoparticles were washed a few times with deionized water and dried in a vacuum stove at 50ºC short-term.

Synthesis of Fe-cholecalciferol NPs:

From the outset, 100 mg of Fe-cholecalciferol NPs were dissolved in DMSO (Dimethyl sulfoxide) (15 mL) and afterward sonicated for 10 min in a sonicating shower at 60ºC. At that point, triethylamine was added until the pH arrived at 8.2 and was mixed at 37ºC in dimness short-term [11, 12]. At long last, these nanoparticles were isolated from the fluid arrangement by an outside magnet and washed multiple times with deionized water.

CHARACTERIZATION OF THE Fe-cholecalciferol NPs:

FTIR analysis:

Fourier change infrared spectroscopy was acquired utilizing a Bruker, Tensor 27 (Biotage, Germany) FTIR spectrometer to affirm the synthetic design of tests. The FTIR spectra were examined somewhere in the range of 4,000 and 400 cm−1 at a goal of 4 cm−1 in the conveyance mode.

Structure characterization:

The XRD designs were acquired by D8 Advance of Bruker AXS diffractometer from Germany with the Bragg point going from 10o to 80o with Cu Kα1 radiation (λ = 1.54056 Å) as the X-beam source (40 mA, 20 kV).

Determination of particle size:

The size and morphology of MNPs were examined by TEM Cambridge 360-1990 Stereoscan Instrument-EDS from the United States.

Thermal analysis:

Thermal stability was determined by TGA (Linseis STA PT 1000, Germany). Warm soundness was dictated by TGA (Linseis STA PT 1000, Germany). The thermograms of TGA were gotten in the temperature scope of RT up to 700ºC under nitrogen air. Additionally, warm examination of nanoparticles was gained by DSC (Mettler Toledo, model Star SW 9.30, Schwerzenbach, Switzerland) [13]. Tests were warmed in the temperature scope of 30–300oC with a pace of 15ºC/min.

Determination of cholecalciferol in Fe-cholecalciferol NPs:

To measurement of cholecalciferol in the Fe-cholecalciferol nano-particles surface, bright noticeable (UV–Vis) spectroscopy was applied. From the outset, 2.3 mg/mL of Fe-cholecalciferol nano-particles with 2.3 mg/mL of proteinase K as catalyst were scattered in PBS (1 mL) and were placed in a dialysis pack (sub-atomic weight 12 kDa). At that point, this pack was submerged in PBS (5 mL) with pH = 7.4. From that point onward, it was hatched on a shaker at 37^{O}C. To get the estimation of cholecalciferol, UV–Vis spectrophotometer (Thermo Fisher Scientific, Madison, model GENESYSTM 10S) was utilized at a frequency of 280 nm [14,19] and the outcomes were contrasted and the adjustment bend arranged previously.

Preliminary Trial Batches for selection of Permeation Enhancers:

The skin flux of cholecalciferol got without penetration enhancer was 75.25µg/cm^2/hr and it was not adequate to gain focused on flux, for kept up the helpful convergence of medication up to foreordained period. In this manner, in this current examination work recommended from writing survey two basic oils as Permeation enhancers to be specific DMSO [15] and DMF were select and advanced for the improvement in skin flux. Details PE-1 to PE-7 assessed with differing convergences of DMSO thus for the choice of viable Permeation enhancer.

Preliminary Screening of Excipients for Formulation of cholecalciferol Loaded Transdermal Patch:

Preliminary Trial Batches for Selection of Polymers:

Primer preliminary trial batch ERS1 to H3, arranged by solvent evaporation method for choice of different fix framing polymers and its concentration. In which groups ERS1 to ERS3 were get ready for the choice of eudragit RS 100 (ERS 100) conc., ERL1 to ERL3 were set up for the determination of

eudragit RL 100 (ER) conc., H1 to H3 were set up for the choice of various evaluation and concentration of HPMC K15M. For the planning of patches, chose polymers previously gauged and afterward totally scattered into 8 ml of water, at long last this polymeric arrangement saved aside for two hrs. For the arrangement of medication arrangement sedate was totally disintegrate into 2 ml ethanol. This medication solution included into above polymeric solution, and mixed the blend until clear dispersion structure. Later into this dispersion plasticizer was included. This reasonable dispersion at long last poured in the petri plate, which recently greased up with tween 80. This petriplate dried at room temperature in dull condition for the time being. For uniform dissipation of the dissolvable, a transformed pipe kept on the petri plate [16]. After complete drying the dried movies were expelling from the petri-plate and the patches cut into a 4 cm^2 are. Here biaxial arranged polyethylene film was use as a backing membrane and lustrous paper was use as a delivery liner. At long last, the prepared patches were put away in desiccators for additional assessment studies.[66] Compositions of various plans speak to in Table 6.1.3 arranged patches assessed for physicochemical properties.

Table 2 Preliminary trial batches of Polymers

Ingredient(s) (mg)	ERS1	ERS2	ERS3	ERL1	ERL2	ERL3	H1	H2	H3
cholecalciferol	24	24	24	24	24	24	24	24	24
ERS100	100	200	300	-	-	-	-	-	-
ERL100	-	-	-	100	200	300	-	-	-
HPMC K15	-	-	-	-	-	-	100	200	300

Preliminary Trial Batches for the Selection of Plasticizers

Starter preliminary batches PG1 to DBT3 were set up for the determinations of plasticizer focuses. Here, three plasticizers specifically propylene glycol (PG1 to PG3), PEG 400 (PEG1 to PEG3), and DBT (DBT1 to DBT3) were attempted at 3 distinct focuses, 10 % w/w, 15 % w/w, and 20 % w/w individually. All groups were set up with 300 mg ERS 100, 24mg cholecalciferol, 2 ml ethanol and 8 ml water [17].

Table 3 Preliminary trial batches of Plasticizers

Ingredient(s) (mg)	PG 1	PG 2	PG 3	PEG1	PEG2	PEG3	DBT1	DBT2	DBT3
cholecalciferol	24	24	24	24	24	24	24	24	24
PG	10	15	20	-	-	-	-	-	-
PEG400	-	-	-	10	15	20	-	-	-
DBT	-	-	-	-	-	-	10	15	20

Table 4: 3^2 Full Factorial Design Layout of Transdermal Patch of Cholecalciferol Batches S1-S9

3^2 full factorial Design		
Batch No.	Independent variables	
	X_1	X_2
S1	-1	-1
S2	-1	0
S3	-1	1
S4	0	-1
S5	0	0
S6	0	1
S7	1	-1

S8	1	0
S9	1	1
Concentration of independent variables		
Level	fixed weight of Polymer 300 mg (ratio 2:1) (ERL100:HPMC K15)	DMSO Concentration in (%w/w)
-1	250:50	10
0	225:75	20
1	200:100	30

Method of Preparation of Transdermal Patch of Batches S1-S9 Using 3^2 Full Factorial Designs:
The transdermal patches containing cholecalciferol were readied utilizing various proportions of ERL 100 and HPMC K15M. The polymers focus was change with this proportion of 250:50, 225:75 and 200:100 by keeping the consistent load of polymer 300 mg with proportion (2:1) of ERS100/ERL 100: HPMC K15M, than permitted to grow for two hrs in water. According to calculation of dose and drug permeability study, precisely gauged measure of cholecalciferol 24 mg disintegrated in ethanol and this medication arrangement included into the polymeric arrangement with nonstop mixingutilizing attractive stirrer. At that point propylene glycol and DMSO consolidated as plasticizer and permeation enhancer separately. The inverted funnel was kept over the petri plate for uniform dissipation at room temperature for 24 hrs in dark condition, after complete drying biaxial arranged polyethylene film utilized as a backing membrane and a smooth glossy paper utilized as a delivery liner. At long last the readied patches expelled from the petri plate and cut into 4 cm^2 regions backing layer and delivery liner was connected and spread it with an aluminum foil [18, 23]. Finally spread, patches put into zipper pack firmly close it and put away into desiccators for further assessment examines.

Table 5: Formulation of cholecalciferol Loading Factorial Design Batches S1 to S9

Batch code	S1	S2	S3	S4	S5	S6	S7	S8	S9
cholecalciferol (mg)	24	24	24	24	24	24	24	24	24
ERL 100 (mg)	250	250	250	225	225	225	200	200	200
HPMC K15(mg)	50	50	50	75	75	75	100	100	100
Water (mL)	11	11	11	11	11	11	11	11	11
Ethanol (mL)	10	10	10	10	10	10	10	10	10
PG (%) w/w of dry polymer Wt	20	20	20	20	20	20	20	20	20
DMSO (%)w/w of dry polymer Wt	10	20	30	10	20	30	10	20	30

Evaluation of TDDS

Thickness of the patch:

The thickness of the medication stacked fix was estimated in various focuses by utilizing an micrometer screw gauge and decides the normal thickness and standard deviation for the equivalent to guarantee the thickness of the readied patch [19,22].

Drug content:

The amount of drug present in the patch was determined by dissolving the patch in 100 ml of phosphate buffer pH 6.8. At that point the arrangement is to be separated through a channel medium and dissect the medication utilizing (UV method) at 280 nm [19].

Percentage Moisture content:

The prepared patches were weighed exclusively and to be kept in a desiccator containing melded calcium chloride at room temperature for 24 hrs. After 24hrs the movies are to be rechecked and decide the rate dampness content from the beneath referenced formula.

$$\text{Percentage moisture content} = \frac{\text{Initial weight- Final weight}}{\text{Final weight}} \times 100$$

Percentage Moisture uptake:

The weighed patches were kept in a desiccator at room temperature for 24 hrs containing saturated solution of potassium chloride in order to maintain 84% RH. After 24 hrs the films are to be reweighed and determine the percentage moisture uptake from the below mentioned formula [20, 23]

$$\text{Percentage moisture uptake} = \frac{\text{Final weight- Initial weight}}{\text{Initial weight}} \times 100$$

Water vapor permeability:

Glass vials of 5 ml capacity were washed thoroughly and dried to a constant weight in an oven. About 1g of fused Calcium chloride was taken in the vials & the polymer films were fixed over the brim with the help of an adhesive tape. Then the vials were weighed and stored in a humidity chamber at 85 % RH [22] condition for a period of 24 hours. The vials were removed and weighed at various time intervals like 3, 6, 12, 18 and 24hrs to note down the weight gain.

Weight uniformity:

The prepared patches were dried in oven at 60° for 24 hrs before testing. A specified area of patch isto be cut in different parts of the patch and weigh in digital balance [22, 23]. The average weight and standard deviation values are to be calculated from the individual weights.

Folding endurance:

A strip of specific area was cut evenly and repeatedly folded at the same place till it broke. The number of times the film could be folded at the same place without breaking gave the value of the folding endurance [22].

Percentage Elongation break test:

The percentage elongation break was determined by noting the length just before the break point, the percentage elongation can be determined from the below mentioned formula.

$$\text{Elongation percentage} = \frac{L1\text{-}L2}{L2} \times 100$$

Where, L1is the final length of each strip and L2 is the initial length of each strip

Weight variation:

The assessment of weight variation was performed by weighing individually drug loaded five patches of every formulation on a digital balance [22, 23]. The average weights were calculated and the standard deviation from the average weights measured.

Tensile strength:

Tensile strength of the prepared patches was measure by privately collected instrument. The tensile strength of the patch was estimated utilizing privately gathered instrument. In which one side of patch fixed into the iron screens and another side associated with the paper holder where snare wasembedded. One string was attached with this snare, which disregarded the pulley and a little dish appended to the opposite end for holding the weight. Little pointer was appended to the string, which goes over the scale attached on the base plate. For estimation of tensile strength patch was pulled and loads were bit by bit added to the dish to build the pulling power till the patch was broken. All out loads required to break the patch considered as a power, placing the estimation of power into the equation elasticity was measure [24]. Tensile strength= × (+/). Where, F is power required to break; a, b, and L are width, thickness and length of patch individually and l is extension of patch at break point.

Flatness:

A transdermal patch ought to have a smooth surface and ought not choke with time. To assess this property flatness study was perform. In this, study one segment of patch cut from the middle and two from each side. The length of each strip was estimated and variety long note down. Zero percent narrowing will be proportionate to 100 percent flatness [23, 24].

$$\text{Percentage constriction} = \frac{I1 - I2}{I1} * 100$$

pH:

Patch was set in a beaker and was soaked with 10 mL of distilled water and saved for 30 minutes. ThepH was measure subsequent to bringing the terminal of the pH meter in contact with the outside of the plan and permit equilibrate for 2 to 3 minutes [22].

In-vitro drug release studies:

The in vitro release study was done with the semi porous film utilizing Franz diffusion cell. The chamber comprises of two chambers, the giver and the receptor compartment. The giver compartment was open at the top and was presented to air. The temperature was kept up at 37 ± 0.5ºC and receptor compartment was furnished with testing port. The dispersion medium utilized was phosphate support (pH 7.4).

Diffusion cell:

The diffusion considers were done to get a thought of pervasion of medication through hindrance from the transdermal framework. In vitro investigations are additionally accomplished for TDDS advancement. Generally, two kinds of diffusion cells are utilized as flat and vertical. The Franz and Keshary Chien (K-C) sort of diffusion cells are of flat kind of cells. In this work, K-C kind of diffusion cell was utilized. Diffusion cells for the most part include two compartments, one containingthe dynamic segment (contributor compartment) and the other containing receptor arrangement (receptor compartment), isolated by obstruction for example mice stomach skin. The cell comprised of examining port and temperature looking after coat. The outlet and delta was associated with latex tube so the coat had stale water inside and heat was given by hot plate. The treated steel pin was utilized to mix the receptor arrangement utilizing attractive stirrer [25, 27]. The mice stomach skin was put on receptor compartment and the two compartments held tight by clamps.

RESULT:

Synthesis of iron Nanocarrier:

As announced previously, the attractive nanocarrier was incorporated here utilizing an in situ and one-pot with controlled co-precipitation strategy (Figure 5.5). At that point, functionalization with arginine was performed. From that point onward, DCX was formed as a generally utilized anticancer medication to this attractive nanocarrier with a covalent amide bond (carbodiimide science strategy).

The measure of Chol-formed was 8.25 ± 0.29. At the subsequent stage, nanoparticles were portrayed by a few strategies. At last, we explored their anticancer impact on MCF-7 cell line that has over communicated folate receptors by MTT measure. Additionally, we considered their cell cytotoxicity on 4T1 cell line for in vivo concentrate later on.

Fourier transform infrared spectroscopy:

Fourier transform infrared spectroscopy spectra were used to exhibit functionalization of iron-NPs with arginine and formation of cholecalciferol to them. Functionalization of iron oxide nanoparticles with arginine is obvious from the examination of FTIR range of Fe_3O_4, Fe-Arg, DCX, and Fe-Arg- DCX as demonstrated in Figure 1.



Figure 1: FTIR spectra of samples. FTIR, Fourier transform infrared spectroscopy

Preliminary Studies of Pure Drug Permeation:

The penetration flux of cholecalciferol across wistar rodent saw as 53.01 µg/cm2/hr. The diffusion coefficient was 0.0116 x10-8 cm^2/hr and penetrability coefficient was 0.45 X 10^{-2}/cm/hr. The acquired information of medication release study proposed that pure medication having adequate permeation through the skin; however the got flux was insufficient to keep up consistent state plasma conc. of medication all through the treatment. Hence, further improvement in flux accomplishes utilizing fundamental oils as normal permeation enhancers. In this current exploration work fundamental oils to be specific DMSO was select and attempted. Results spoke to in Figure 2.



Figure 2: Comparative Drug Release Profile of Batches L1-L2

Improvement in Permeability Using Permeation Enhancers:

Gotten consequences of bunches PEC1 to PEC7 for development in penetration with various centralization of chose DMSO as an enhancers uncovered that permeation increment with increment in convergence of basic oils since, they improve the diffusion of medication particles through the various layers of skin by parceling into the lipid cell of layer corneum. This was obvious from the aftereffects of cholecalciferol pemeation at 16 hrs from PEC2 to PEC7 with DMSO thus at various groupings of 10 % w/w and 20 % w/w of all out weight of polymer dry weight, results appeared in Figure 3. The higher diffusion was acquired by provided rising request of DMSO. It likewise demonstrates that DMSO as was not adequate to accomplish want permeation flux for controlled delivery up to 16 hrs. Then again, batch PEC7 with 20% w/w DMF accomplishes the/cm^2/hr, which was adequate for controlled arrival of medication just as to keep up helpful plasma level. In this way, DMSO focus chose as a one autonomous variable for additional enhancement of transdermal flux utilizing 3^2 full factorial structures.



Figure 3: Comparative permeation Profile of Batches PEC1-PEC7

Preliminary Trial Batches for the Polymers

Preliminary trial batches ERS1 to H9 were prepared for the selection of patch forming polymer and its concentration.

Table 6 Physicochemical Parameters of Batches ERS1 to ERL3

Batch code	Weight variation (mg)	Thickness (mm)	Drug content (%)	Flatness (%)	Folding Endurance
ERS1	360 ± 0.732	0.10 ± 0.11	97.26 ± 0.21	99.8 ± 0.22	358 ± 0.23
ERS2	373 ± 0.516	0.14 ± 0.22	98.34 ± 0.87	98.9 ± 0.23	362 ± 0.21
ERS3	307 ± 0.527	0.15 ± 0.12	98.84 ± 0.80	98.4 ± 0.24	354 ± 0.23
ERL1	346 ± 0.087	0.16 ± 0.23	97.52 ± 0.40	99.7 ± 0.26	356 ± 0.22

ERL2	388 ± 0.527	0.22 ± 0.24	98.68 ± 0.49	99.8 ± 0.27	368 ± 0.21
ERL3	378 ± 0.320	0.18 ± 0.21	97.79 ± 0.52	98.1 ± 0.17	346 ± 0.20

(Where n = 3, Mean ± SD)

Table 7 Physicochemical Parameters of Batches H1 to H9

Batch code	Weight variation (mg)	Thickness (mm)	Drug content (%)	Flatness (%)	Folding Endurance
H1	360 ± 0.732	0.10 ± 0.11	97.26 ± 0.21	99.8 ± 0.22	358 ± 0.23
H2	373 ± 0.516	0.14 ± 0.22	98.34 ± 0.87	98.9 ± 0.23	362 ± 0.21
H3	370 ± 0.527	0.15 ± 0.12	98.84 ± 0.80	98.4 ± 0.24	354 ± 0.23
H4	346 ± 0.087	0.16 ± 0.23	97.52 ± 0.40	99.7 ± 0.26	356 ± 0.22
H5	388 ± 0.527	0.22 ± 0.24	98.68 ± 0.49	99.8 ± 0.27	368 ± 0.21
H6	378 ± 0.320	0.18 ± 0.21	97.79 ± 0.52	98.1 ± 0.17	346 ± 0.20
H7	370± 0.320	0.10 ± 0.11	97.28 ± 0.21	93.8 ± 0.22	249 ± 0.27
H8	353 ± 0.231	0.11 ± 0.19	96.84 ± 0.29	93.1 ± 0.28	263 ± 0.29
H9	337 ± 0.253	0.13± 0.21	97.66 ± 0.24	94.4 ± 0.24	254 ± 0.21

Physicochemical Evaluations of Matrix Patch of Batches S1 to S9
Factorial design batches S1 to S9 were evaluate for following physicochemical parameters.

Table 8 Physicochemical Evaluation of Cholecalciferol Loading Batches S1 to S9

Batch code	Weight variation (mg)	Thickness (mm)	Folding endurance	% moisture Uptake	% moisture Loss
S1	360 ± 0.732	0.10 ± 0.11	358 ± 0.23	1.86 ± 0.07	2.78 ± 0.09
S2	373 ± 0.516	0.14 ± 0.22	362 ± 0.21	2.60 ± 0.06	1.86 ± 0.08
S3	369 ± 0.527	0.15 ± 0.12	354 ± 0.23	2.50 ± 0.18	1.98 ± 0.68
S4	348 ± 0.087	0.16 ± 0.23	356 ± 0.22	2.42 ± 0.12	2.14 ± 0.05
S5	387 ± 0.527	0.19 ± 0.24	368 ± 0.21	1.90 ± 0.30	1.56 ± 0.59
S6	378 ± 0.320	0.18 ± 0.21	346 ± 0.20	1.80 ± 0.05	2.26 ± 0.03
S7	370± 0.320	0.10 ± 0.11	249 ± 0.27	1.63 ± 0.21	2.45 ± 0.06
S8	353 ± 0.231	0.11 ± 0.19	263 ± 0.29	2.72 ± 0.05	1.93 ± 0.02
S9	337 ± 0.253	0.13± 0.21	254 ± 0.21	1.98 ± 0.16	1.80 ± 0.14

(Where n = 3, Mean ± SD)

Table 9 Results of Dependent Variables of batches S1 to S9

Batch code	Code value		Dependent variables		
S1	X1	X2	Y1	Y2	Y3
S2	-1	-1	10.42 ± 0.23	72.18± 0.22	3.51 ± 0.01
S3	-1	0	11.36 ± 0.40	74.56± 0.21	3.62 ± 0.02
S4	-1	1	12.62 ± 0.32	76.21± 0.65	3.65 ± 0.02
S5	0	-1	13.51 ± 0.12	79.02± 0.50	3.70 ± 0.03
S6	0	0	14.26 ± 0.28	81.03± 0.45	3.75 ± 0.03
S7	0	1	15.53 ± 0.20	83.12± 0.06	3.81 ± 0.02
S8	1	-1	16.45 ± 0.63	85.63± 0.41	3.85 ± 0.01
S9	1	0	17.76 ± 0.03	88.01± 0.72	3.92 ± 0.04
	1	1	18.22 ± 0.04	90.22± 0.52	4.98 ± 0.03

(Where n = 3, Mean ± SD)

Analysis of Variance and Model Equations for Thickness of Batches S1 to S9

For response surface analysis, two-way analysis of variance was generated by Design Expert 6.0 software. The Model F-value was more than tabulated F-value (10.86) which implies that the model is significant and the higher value of R^2 (0.997) indicates good fitting of model. The polynomial equation derived for the estimation was mention below.









Figure 4 (A) Normal Plot of residual and (B) Response Surface Plot of Effect of Polymer Fixed Weight Ratio and DMSO on Thickness of Batches S1 to S9

Analysis Of Variance and Model Equations for Drug diffusion:

For response surface analysis, two-way analysis of variance was generated by Design Expert 6.0.8 software. The Model F-value was more than tabulated F-value (3.56) which implies that the model is significant and the higher value of R^2 (0.998) indicates good fitting of model. The polynomial equation derived for the estimation was mention below.

Polynomial Equation1 represents the effects of both the independent variables on % drug released in 1 hour (Q1hr) of batches S1-S9. Positive sign of B factor indicates that % drug diffusion increases with increase in the amount of DMSO. The effect of two independent variables (A and B) compared with each other from the value of coefficients it revealed that amount of DMSO was considered to be a major effective variable for % drug diffusion in from batches S1-S9. Contour plot and 3D response surface plots shown in Figure 7.1.16.





Figure 5: (A) Normal Plot and (B) Response Surface Plot Show the Effect of Polymer Fixed Weight Ratio and DMSO on the Percent Drug Diffusion from Batches S1-S9

Validation of Optimization Design:

Selected criteria for independent and dependent variable for formula optimization

Independent Variables: X1- Polymer fixed weight ratio of ERL100 and HPMC K15M (300 mg) : (50:250, 75:225, 100:200) and X2- DMSO concentration – 10 % w/w, 20 % w/w and 30% w/w. Dependent Variables: (Y1) Thickness – 0.10-0.22 mm, (Y2) Percent drug diffusion in 72.18 to 90.22 %.

Checkpoint Analysis of Batches S1 to S9:

To approve the chose numerical models, checkpoint approval investigation was performed and from the overlay plot, two arrangements of both the free factors were chosen and on the bases of that, two clumps were set up with the amount chose from the overlay plot. The investigation was performed for multiple times and acquired real outcomes mean estimations of each of the three ward factors were contrasted and anticipated qualities, the distinctions were seen as huge (P>0.05). Consequently, acquired real outcomes uncovered that the quadric model is legitimate for connection between hypothetical forecasts of ward factors with the for all intents and purposes got results.

Table 10: Observed and Predicted Results of Checkpoint Validation Analysis

Batch Code			% D Diffusion up to 16 hrs		Thickness	
	X1	X2	Act. value	Pred. value	Act. value	Pred. value
L1	300	20	94.39	90.22	0.15	0.16

For Drug – (tcal) value – 2.20 and (ttab) value – 2.29

DISCUSSION:

Transdermal patch for cholecalciferol was effectively arranged utilizing HPMC K15M and ERL 100 as a patch shaping polymers by solvent evoparation technique and last medication stacked patch was discover by formulation of examinations from the product 9.0 of software. Arranged batch S1 to S9 were assess for various physiochemical parameter. Aftereffects of physicochemical parameter of batches S1 to S9 speak to in Table 7.1.17. Drug loaded patches (4cm^2) were gauging utilizing Digital electronic balance, Shimadzu, Japan. The flatness of 4 cm^2 patches range from 348 ± 0.087 mg to 387 ± 0.527 mg. In all the cases, the determined standard deviation esteems were low which shows thatthe readied patches were uniform in weight, and along these lines all the bunches passed the weight variety according to limits given in legitimate books. Acquired outcomes proposed that medication was consistently scattered in to polymeric scattering. With the assistance of micrometer check, the thickness of fix was measure at six positions and the normal was note down. The consequence of clumps S1to S9 uncovered that there were minor contrasts between the thicknesses of the considerable number of details, it acquired in the middle of 0.10 ± 0.11mm to 0.19 ± 0.24 mm. Cluster S5 shows most elevated thickness and S1 shows least thickness, this occur due to the diversein polymer fixation and conveyance distinction over the petriplate. Medication substance of the transdermal fix was performed to discover the stacking of medication is uniform in the plan or not. Collapsing perseverance of arranged patches was in scope of 346 ± 0.20 to 368 ± 0.21. Contingent on the convergence of propylene glycol and DMSO, aftereffects of collapsing continuance may be contrasted. F-S5 shows most noteworthy collapsing continuance with 368 ± 0.21 demonstrates that the patches had adequate mechanical quality and it would be stay as such during the treatment on the application site. The perfection was measure physically for the readied transdermal fix. An acquired consequence of evenness study proposed that the length of fix strip, when cuts was stay same and It shows 2 to 3% choking in all the nine clusters. Arranged F-S1 to S9 assessed for rate dampness take- up and misfortune just as for pH estimation. The outcomes show that bunch S7 display most reduced dampness take-up estimation of 1.63 ± 0.21% which lessening odds of microbial pollution. Rate dampness misfortune was in scope of 1.56 to 2.78 %, this low moisture loss prevents patches to become brittle. From the acquired outcomes, t (cal) and t (tab) values was seen as 2.20 and 2.29. Here,t (cal) esteem was not as much as t (tab) values for all reactions at all the levels, which proposed that there were no noteworthy contrast between two outcomes. The t test esteem additionally proposed that acquired outcomes are closer to anticipated qualities which shows that, produced model is how much legitimate for optimization of final formulation.

CONCLUSION:

cholecalciferol Solubility suggested that uninhibitedly dissolvable in organic solvents, dissolvable in phosphate support pH 6.8 and for all intents and purposes insoluble in distilled water. The log p

estimation of cholecalciferol 3.7, it was closer to standard worth. Log P value in a range of 1 to 4 indicates higher permeation through the skin. The diffusion coefficient was 0.0116 x10-8 cm^2/hr and penetrability coefficient was 0.45 X 10^{-2}/cm/hr. further improvement in flux accomplishes utilizing fundamental oils as normal permeation enhancers. In this current exploration work specific DMSO and DMF was select. This was obvious from the aftereffects of cholecalciferol pemeation at 16 hrs from PEC2 to PEC7 with DMSO thus at various groupings of 10 % w/w and 20 % w/w of all out weight of polymer dry weight. It likewise that DMF as was not adequate to accomplish want permeation flux for controlled delivery up to 16 hrs. Then again, batch PEC7 with 20% w/w DMSO accomplishes the/cm^2/hr, which was adequate for controlled arrival of medication just as to keep up helpful plasma level. The outcomes recommended that there was no much contrast in thickness of the considerable number of batches. Which uncovered that thickness were increments as hydrophilic bit of polymer increments. If there should be an occurrence of weight variety, study drug loaded patche (4 cm^2) were gauging utilizing electronic balance. The weight of all groups discovered uniform in a range of 321 mg to 363 mg. drug content outcomes additionally discovered uniform in all clusters in arange of 97 % to 98 %, it proposed that the medication and polymers consistently distributed in dispersion. Generally speaking, the aftereffects of starter preliminary result proposed that batches arranged with ERL 100 shows great mechanical properties contrast with different polymers however helpless glue properties. On the opposite side bunches arranged with HPMC K15M shows excellent adhesive and mechanical quality, yet HPMC K15M alone was not adequate to plan adaptable, uniform and straightforward patches. Aftereffects of batches DBT1 to DBT3 uncovered that all the batches have great physicochemical boundaries however; they were hard, dry and less adaptable. Consequences of batches PEG1 to PEG3 additionally proposed that acquired patches were helpless adaptability and mechanical quality contrasted with PG plans. Consequences of bunches PG1 to PG3 show that patches were have acceptable. Some DMSO re preliminary completed to choose ideal centralization of PG with, 30% and 40% w/w however got patches didn't show any acceptable outcomes because of their exceptionally hygroscopic and clingy nature. Transdermal patch for cholecalciferol was effectively arranged utilizing HPMC K15M and ERL 100 as a patch shaping polymers by solvent evoparation technique and last medication stacked patch was discover by formulation of examinations from the product 6.0.8 of software. The flatness of 4 cm^2 patches range from 348 ± 0.087 mg to 387 ± 0.527 mg. The consequence of clumps S1to S9 uncovered that there were minor contrasts between the thicknesses of the considerable number of details, it acquired in the middle of 0.15 ± 0.11mm to 0.19 ± 0.22 mm. Cluster S5 shows DMSO elevated thickness and S1 shows least thickness, this occur due to the diverse in polymer fixation and conveyance distinction over the petriplate. Collapsing perseverance of arranged patches was in scope of 321 ± 0.20 to 363 ± 0.21. Contingent on the convergence of propylene glycol and DMSO, aftereffects of collapsing continuance may be contrasted. Clumps S5 shows DMSO noteworthy collapsing continuance with 363 ± 0.21 demonstrates that the patches had adequate mechanical quality and it would be stay as such during the treatment on the application site. The outcomes show that bunch S7 display reduced dampness take-up estimation of 1.63 ± 0.21% which lessening odds of microbial pollution. Rate dampness misfortune was in scope of 1.56 to 2.78 %, this low loss prevents patches to become brittle. Permeation kinetic analysis, for example, penetration flux, permiability coefficient and enhancement proportion were determined. The outcomes uncovered that batch S9 containing 30 %/cm^2/hr and 94.39 % released in 16 hrs. The aftereffects of ex-vivo discharge likewise proposed that the concentration of DMSO and PG both had significant impact on drug release. For response surface analysis, two-way analysis of variance was generated by Design Expert 6.0.8 software. The DMSO F-value was measure than tabulated F-value (10.86) which implies that the DMSO is significant and the higher value of R^2 (0.994) indicates good fitting. The effect of two independent variables (A and B) compared with each other from the value of coefficients it revealed that amount of DMSO was

considered to be a major effective variable for % drug released from batches S1-S9. From the acquired outcomes, t (cal) and t (tab) values was seen as 2.20 and 2.29. Here, t (cal) esteem was not as much as t (tab) values for all reactions at all the levels, which proposed that there were no noteworthy contrast between two outcomes. Regression coefficient additionally recommended that medication discharge from the patch follow zero request and from the patch tranquilize was discharge ceaselessly in a controlled way up to 16 hrs. The correlation coefficient (R^2) of Higuchi's DMSO was seen as 0.9622 that shows diffusion of medication from the readied patches. In this manner, the chose batch S9 followed zero order.

Conflict of interest: No potential conflict of interest was declared by the authors.Acknowledgement:

……

Author Contribution: All the authors have equally contributed in this manuscript.

REFERENCES:

1. Jain, N.K., 1997. Controlled and Novel drug delivery CBS Publisher and distributor, 1 st ed., 100-126.
2. Jalwal, P., Jangra, A., Dahiya, L., Sangwan, Y., Saroha R., 2010. A review on transdermal patches. T. Ph. Res., 3, 139-149.
3. Wilson, K.J.W., Waugh, A., In:Ross and Wilson: 1996. Anatomy and Physiology In Health and Illness", 8th ed, Churchill Livingstone, 360-366.
4. Allen, L. V., Popovich, N. G., Ansel, H. C., 2005. Pharmaceutical dosage forms and drug delivery systems, Lippincott Williams & wilkins, 8th ed, 298-315.
5. Sanjoy, M., Thimmasetty, j., Ratan, G. N.,Kilarimath, B. H., 2011. Formulation and evaluation of Crvedilol transdermal patches. Int. Res. J. Pharm. 2 (1), 237-248.
6. Bhosle, N. R., Sharwaree, H. R., Bhosale A. V., 2011, Formulation and Evaluation of Transdermal patches of Ropinirole HCl, Res. J. Pharm, Bio. Chem., 2 (1) 138-148.
7. Jamakandi VG, Mulla JS, Vinay BL, Shivakumar HN. Formulation, characterization, and evaluation of matrix-type transdermal patches of a model antihypertensive drug. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm. 2014 Aug 28;3(1).
8. Guyot M, Fawaz F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. International Journal of Pharmaceutics. 2000 Jun 20;204(1-2):171- 82.
9. Wang J, Ruan J, Zhang C, Ye Y, Cai Y, Wu Y. Development and evaluation of the Sinomenine transdermal patch. Pakistan journal of pharmaceutical sciences. 2008 Oct 1;21(4).
10. Aggarwal G, Dhawan S, Harikumar SL. Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine. Pharmaceutical development and technology. 2013 Aug 1;18(4):916-25.
11. Parivesh S, Sumeet D, Abhishek D. Design, evaluation, parameters and marketed products of transdermal patches: A review. J. Pharm. Res. 2010 Feb;3(2):235-40.
12. Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. European Journal of Pharmaceutics and Biopharmaceutics. 2006 Aug 1;64(1):1-8.
13. Kavitha K, Rajendra MM. Design and evaluation of transdermal films of lornoxicam. International Journal of Pharma and Bio Sciences. 2011 Jun 30;2(2):54-62.

14. Furuishi T, Io T, Fukami T, Suzuki T, Tomono K. Formulation and in vitro evaluation of pentazocine transdermal delivery system. Biological and Pharmaceutical Bulletin. 2008 Jul 1;31(7):1439-43.
15. Gutschke E, Bracht S, Nagel S, Weitschies W. Adhesion testing of transdermal matrix patches with a probe tack test–In vitro and in vivo evaluation. European journal of pharmaceutics and biopharmaceutics. 2010 Aug 1;75(3):399-404.
16. Saroha K, Yadav B, Sharma B. Transdermal patch: A discrete dosage form. Int J Curr Pharm Res. 2011;3(3):98-108.
17. Ravikumar R, Ganesh M, Senthil V, Ramesh YV, Jakki SL, Choi EY. Tetrahydro curcumin loaded PCL-PEG electrospun transdermal nanofiber patch: Preparation, characterization, and in vitro diffusion evaluations. Journal of Drug Delivery Science and Technology. 2018 Apr 1;44:342-8.
18. Pongjanyakul T, Prakongpan S, Priprem A. Acrylic matrix type nicotine transdermal patches: in vitro evaluations and batch-to-batch uniformity. Drug development and industrial pharmacy. 2003 Jan 1;29(8):843-53.
19. Alam MI, Alam N, Singh V, Alam MS, Ali MS, Anwer T, Safhi MM. Type, preparation and evaluation of transdermal patch: A review. World Journal of Pharmacy and Pharmaceutical Sciences. 2013 May 21;2(4):2199-233.
20. Cherukuri S, Batchu UR, Mandava K, Cherukuri V, Ganapuram KR. Formulation and evaluation of transdermal drug delivery of topiramate. International journal of pharmaceutical investigation. 2017 Jan;7(1):10.
21. Prabhakar D, Sreekanth J, Jayaveera KN. Transdermal drug delivery patches: a review.Journal of Drug Delivery and Therapeutics. 2013 Jul 17;3(4):231-21.
22. Taghizadeh SM, Soroushnia A, Mohamadnia F. Preparation and in vitro evaluation of a new fentanyl patch based on functional and non-functional pressure sensitive adhesives. AAPS PharmSciTech. 2010 Mar 1;11(1):278-84.
23. Mittal A, Sara US, Ali A, Mohammed A. Design, development, physicochemical, in vitro and in vivo evaluation of monolithic matrix type transdermal patches containing nitrendipine. Pharmaceutical development and technology. 2009 Aug 1;14(4):422-34.
24. Sonpal RN, Mohan S, Selvaraj S. Formulation and Evaluation of Iontophoretic Transdermal Delivery of Dilti-azem Hydrochloride. International Journal of Research in Pharmaceutical Sciences. 2010 Jul 25;1(3):338-44.
25. Keleb E, Sharma RK, Mosa EB, Aljahwi AA. Transdermal drug delivery system-design and evaluation. International Journal of Advances in Pharmaceutical Sciences. 2010 Jul 1;1(3).
26. Zhang Y, Xu DH, Ma Z, Chen Y, Zhao JJ, Xu SB. Preparation and evaluation in vivo and in vitro of glimepiride gel-matrix controlled-release patch. Yao xue xue bao= Acta pharmaceutica Sinica. 2004 Aug 1;39(8):640-4.
27. Gannu R, Vamshi Vishnu Y, Kishan V, Madhusudan Rao Y. Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. Current Drug Delivery. 2007 Jan 1;4(1):69-76.